In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Body-based burial: Students imagine urns made from blood and hair
In Slovenia, students at University of Ljubljana have used biobased materials for a variety of design projects, including a biodegradable urn made of blood...
Uttar Pradesh eyes cow poop plastics to boost rural economy
In Uttar Pradesh, a government project is collecting cow dung to convert into usable products such as bioplastics, textiles, and paper.
The Press Trust...
Luxury brand Velvet Eyewear lauds advances in biobased acetate
In California, luxury women’s eyewear brand Velvet Eyewear has unveiled its first biobased eyewear collection.
Crafted from renewable sources like wood pulp and cotton...